ENDRA Life Sciences Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M |
| Operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M |
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M | -$11.5M |
| Pretax income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M |
| Income tax expense | — | $0 | $0 | $0 | $0 |
| Net income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M |
| Balance Sheet | |||||
| Current assets | $967,969 | $3.4M | $3.0M | $5.4M | $12.1M |
| Total assets | $3.9M | $4.5M | $6.8M | $9.3M | $12.9M |
| Current liabilities | $750,956 | $605,230 | $903,095 | $1.7M | $1.5M |
| Total liabilities | $1.6M | $1.9M | $1.1M | $2.1M | $2.1M |
| Stockholders' equity | $2.3M | $2.6M | $5.7M | $7.2M | $10.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$5.2M | -$7.4M | -$9.5M | -$12.8M | -$11.1M |
| Depreciation and amortization | $44,045 | $46,489 | $123,726 | $96,661 | $116,238 |
| Stock-based compensation | $329,409 | $571,924 | $996,430 | $1.2M | $1.4M |
| Capital expenditure | $17,280 | $16,000 | $33,884 | $202,577 | $45,000 |
| Free cash flow | -$5.2M | -$7.4M | -$9.6M | -$13.0M | -$11.2M |
Shares outstanding 1.3M · Free float 63.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.